1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sage Ready To Turn Over Cards On Bets Outside Of Depression

Five Clinical Trial Readouts Expected In 2024

 
• By Mandy Jackson

Sage has two postpartum depression drugs on the market, but will read out mid-stage trials this year for two candidates in Huntington’s, Parkinson’s and Alzheimer’s diseases and essential tremor.

Set of abstract dots and lines brain logotypes concept
Sage has multiple brain health program readouts in 2024 • Source: Shutterstock

The US Food and Drug Administration review last year regarding Sage Therapeutics, Inc./Biogen, Inc.’s Zurzuvae (zuranolone) was not a sure bet and resulted in a split decision – approval for postpartum depression (PPD), but not for major depressive disorder (MDD). This year, Sage is focused on Zurzuvae’s PPD launch, while also preparing to turn over the cards on two new bets, both outside of the depression market.

Key Takeaways

  • 2024 is a big one for Sage as it is the first full launch year for Zurzuvae (zuranolone) in postpartum depression, but the company is also expecting several data readouts from its R&D pipeline.

Zurzuvae, an oral positive allosteric modulator (PAM) of the GABA-A receptor, is Sage’s second drug for PPD after the approval...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

More from R&D

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.